A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study) — React-G

Early Stage Breast Cancer Clinical Trial

Official title:
A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)

Status Completed

Clinical Trial Summary

In patients with early-stage breast cancer, chemotherapy has substantially improved survival rates for breast cancer patients. Improvements in outcomes, however, are compromised by the considerable toxicities associated with chemotherapy, most notable being neutropenia. Neutropenia is the presence of abnormally few white blood cells, leading to increased susceptibility to infection and can require hospitalization and need for intravenous antibiotics and is sometimes fatal. Febrile neutropenia can also be associated with treatment delays and dose reductions, potentially compromising treatment efficacy. Patients can receive medication to reduce the risk of febrile neutropenia, such as Neupogen (Filgrastim) as a daily injection for 5, 7, or 10 days. Since there is genuine uncertainty amongst healthcare professionals as to which administration schedule of Neupogen is better, investigators are performing a randomized study in which patients are put into a group by chance to give participants one of three standards of Neupogen daily injection. Neupogen can cost approximately $200 per injection, so if a physician prescribes 10 days for 8 cycles of treatment this can cost $16,000 compared to a 5 day prescription which would cost half this. In addition to cost savings, many patients are not able to give themselves injections on a daily basis and require nursing resources which are utilized at high-cost. This study will use an "integrated consent model" that involves an "oral consent" rather than a written informed consenting process in order to increase the number of patients who may participate while performing a study at a lower cost. While determining the optimal treatment will improve patient comfort and acceptability, using the minimal safe duration of administration may also offer cost savings.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02428114
Study type	Observational
Source	Ottawa Hospital Research Institute
Contact
Status	Completed
Phase	N/A
Start date	May 2015
Completion date	March 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02816112` - Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia	Phase 4
Completed	`NCT02816164` - A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia	Phase 4
Completed	`NCT03946683` - Cyberknife for Early Stage Breast Cancer	N/A
Recruiting	`NCT04458532` - Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer	N/A
Completed	`NCT01162200` - Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer	Phase 1
Completed	`NCT01965522` - Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer	Phase 2
Completed	`NCT00309569` - Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients	Phase 3
Terminated	`NCT01545648` - Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer	Phase 2
Active, not recruiting	`NCT02685332` - Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA	Phase 1
Completed	`NCT02159157` - A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer	N/A
Completed	`NCT01871116` - POWER-remote Weight Loss Program in Early Stage Breast Cancer	N/A
Terminated	`NCT01166581` - Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates	N/A
Recruiting	`NCT06311357` - Percent Weight Change in the Medical Supplement Group of Early Breast Cancer	N/A
Terminated	`NCT02364960` - Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)
Active, not recruiting	`NCT03561454` - A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients
Completed	`NCT02485678` - A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer	N/A
Active, not recruiting	`NCT02297672` - Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant	N/A
Completed	`NCT02335671` - Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy	N/A
Completed	`NCT03102307` - Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD)
Recruiting	`NCT04607473` - ABUS for Early-stage Breast Cancer	N/A